Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2012European Journal of Cancer SupplementsOpen Access

Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice

View Full Paper
Ask AI
Bookmark
Share

Authors

GVGalina VelikovaUniversity of LeedsCCCorneel CoensEuropean Organisation for Research and Treatment of CancerFEFabio EfficaceFondazione Gimema Onlus

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Velikova et al. (2012) studied this question.

synapsesocial.com/papers/6a83cf8967f654fd873c1cfbhttps://doi.org/10.1016/s1359-6349(12)70023-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study2004 · 60 citations
  2. 2Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)2010 · 55 citations